Previous Article | Next Article 
Mol Cell Biol, August 1998, p. 4883-4898, Vol. 18, No. 8
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
mcl-1 Is an Immediate-Early Gene Activated by the
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Signaling
Pathway and Is One Component of the GM-CSF Viability
Response
Jyh-Rong
Chao,1 2
Ju-Ming
Wang,1 3
Shern-Fwu
Lee,4
Hsien-Wei
Peng,1 5
Yi-Hung
Lin,1 3
Chiang-Hung
Chou,1
Jian-Chiuan
Li,1
Huei-Mei
Huang,3 4
Chen-Kung
Chou,6
Min-Liang
Kuo,2
Jeffrey J.-Y.
Yen,4 and
Hsin-Fang
Yang-Yen1 *
Institute of Molecular
Biology1 and
Institute of Biomedical
Sciences,4
Academia Sinica, Institute of
Toxicology2 and
Institute of Molecular
Medicine,5 National Taiwan University Medical
School,
Graduate Institute of Life Science, National
Defense Medical Center,3 and
Department
of Medical Research, Veterans General
Hospital,6 Taipei, Taiwan
Received 4 November 1997/Returned for modification 18 December
1997/Accepted 5 May 1998
 |
ABSTRACT |
mcl-1, a bcl-2 family member, was
originally identified as an early gene induced during differentiation
of ML-1 myeloid leukemia cells. In the present study, we demonstrate
that Mcl-1 is tightly regulated by the granulocyte-macrophage
colony-stimulating factor (GM-CSF) signaling pathway. Upon deprivation
of survival factor from TF-1 myeloid progenitor cells, Mcl-1 levels
quickly dropped prior to visible detection of apoptosis of these cells.
Upon restimulation of these deprived cells with GM-CSF, the
mcl-1 mRNA was immediately induced and its protein product
was accordingly resynthesized. Analysis with Ba/F3 cells expressing
various truncation mutants of the GM-CSF receptor revealed that the
membrane distal region between amino acids 573 and 755 of the receptor
chain was required for mcl-1 induction.
Transient-transfection assays with luciferase reporter genes driven by
various regions of the mcl-1 promoter demonstrated that the
upstream sequence between
197 and
69 is responsible for cytokine
activation of the mcl-1 gene. Overexpression of
mcl-1 delayed but did not completely prevent apoptosis of
cells triggered by cytokine withdrawal. Its down regulation by
antisense constructs overcame, at least partially, the survival
activity of GM-CSF and induced the apoptosis of TF-1 cells. Taken
together, these results suggest that mcl-1 is an
immediate-early gene activated by the cytokine receptor signaling
pathway and is one component of the GM-CSF viability response.
 |
INTRODUCTION |
Cytokines belong to a family of
growth factors that play an important role in regulating the viability,
differentiation, proliferation, and function of various hematopoietic
cells (2). They function by binding to their cognate
receptors and triggering a cascade of tyrosine phosphorylation of both
various known intracellular signaling proteins and the STAT (signal
transducers and activators of transcription) family of transcription
factors (references 12 and 28 and
references therein). In the absence of these cytokines, the majority of
their dependent cells die, at least in culture, by apoptosis
(51), which is one form of cellular suicide that occurs
widely during animal development, tissue homeostasis, and various
disease processes (references 36, 45, 46, and 50 and references therein). Apoptosis is
characterized by distinct morphological changes including cellular
shrinkage, blebbing of the plasma membrane, nuclear condensation, and
endonucleolytic cleavage of the genomic DNA into nucleosome-length
fragments (51).
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and
interleukin-3 (IL-3) are two hematopoietic cytokines produced by
activated T cells and mast cells that are potent growth factors for
multipotential hematopoietic progenitors as well as various other
hematopoietic cells (2). These two cytokines, by binding to
their receptors (composed of one cytokine-specific
subunit and one
common
subunit also shared with the IL-5 receptor), generate both
mitogenic and anti-apoptotic signals. By deletion analysis, GM-CSF has
been shown to activate multiple sets of signaling events through
distinct cytoplasmic domains of the receptor
subunit (39,
40). While the membrane-proximal domain mediates the induction of
c-Myc and is important for cells to progress into the S phase, the
distal cytoplasmic domain is essential for the activation of the
Ras-Raf-mitogen-activated protein (MAP) kinase pathway (40).
The latter pathway is believed to be important for the anti-apoptotic
activity of GM-CSF in hematopoietic cells (16). However, the
exact signaling molecules involved in this pathway still remain
unclear.
Mcl-1, isolated from the differentiating human myeloid leukemia cell
line (19), has sequence similarity to Bcl-2 family members
(18, 37, 47). Substantial studies have shown that overexpression of some members of this family, such as Bcl-2, Bcl-xL, and A1, can inhibit apoptosis induced by various
stimuli (3, 8, 24, 32, 43, 44, 48). Other members, such as
Bax, Bad, and Bak, can actually accelerate apoptosis in cells deprived
of survival factors (4, 7, 15, 33, 53). Mcl-1 belongs to the
former category of the Bcl-2 family, since overproduction of this
protein can delay apoptosis induced by various inducers such as c-Myc
overexpression, growth factor withdrawal, and other cytotoxic agents
(38, 58). Like other members of this family, Mcl-1 also
contains two highly conserved regions designated the BH1 and BH2
domains, which have been shown to be required for the anti-apoptotic
function of Bcl-2 and for heterodimerization with Bax (56).
Unlike Bcl-2, Mcl-1 contains a PEST sequence (19), which
probably presents itself as a labile protein with an estimated
half-life of 1 to 3 h (54). Other than being the product of an early gene activated during tetradecanoyl phorbol acetate
TPA-induced differentiation of human myeloid leukemia cells
(54), the physiological function of Mcl-1 is still unknown. In this study, we show that Mcl-1 in GM-CSF-dependent TF-1 human myeloid progenitor cells is rapidly turned over upon depletion of
survival factors from these cells, and that it can be immediately reinduced upon the addition of GM-CSF. Induction of Mcl-1 expression requires the membrane-distal region of the receptor
chain. We further provide evidence that down-regulation of endogenous Mcl-1 in
TF-1 cells can overcome, at least partially, the survival activity of
GM-CSF and induce apoptosis of these cells. The possible role of Mcl-1
in the GM-CSF signaling pathway is discussed.
 |
MATERIALS AND METHODS |
Cell culture.
TF-1 cells (17) and their
derivatives were maintained in RPMI 1640 supplemented with 10% fetal
bovine serum (FBS), 50 µM
-mercaptoethanol, 2 mM
L-glutamine, 100 U of penicillin G per ml, 100 µg of
streptomycin per ml, and 1 ng of GM-CSF per ml. Human GM-CSF (hGM-CSF)
was kindly provided by Schering-Plough Ltd. For GM-CSF depletion
experiments, TF-1 cells were washed three times in medium without
cytokine and seeded in RPMI 1640 supplemented with 0.5% FBS, 2 mM
L-glutamine, and 50 µM
-mercaptoethanol. During
restimulation experiments, only GM-CSF (10 ng/ml) was added back to the
cells that had been previously deprived of cytokine and placed in
low-serum medium. TF/Bcl-2 and TF/neo are two TF-1 derivatives
overexpressing Bcl-2 and Neo control, respectively. They were generated
by infection with a recombinant retroviral vector carrying
bcl-2 cDNA or the wild-type vector alone (pBabeneo [29]). These were used as a pooled mixture. Mcl10-1
and Mcl10-2 are two TF-1 lines overexpressing human Mcl-1 under the
Tet-off system and were generated as specified by the manufacturer
(Clontech, Palo Alto, Calif.). TFtD1 is a control TF-1 cell line
expressing tetracycline-responsive transcriptional activator (tTA)
alone for this inducible system. Murine IL-3 (mIL-3)-dependent pro-B (BaF/3) cells expressing the human GM-CSF receptor
chain alone or
in combination with the wild-type or c-terminally truncated receptor
chain were maintained in RPMI 1640 supplemented with 10% fetal
bovine serum and 1% conditioned medium from WEHI 3B as a source of
IL-3.
DNA fragmentation assay.
One million cells were collected
after incubation in the desired medium for 24 h and analyzed as
previously described (55). Briefly, cell pellets were
resuspended in 50 µl of the lysis buffer (50 mM Tris-HCl [pH 8.0],
10 mM EDTA, 0.5% Sarkosyl, 500 µg of proteinase K per ml) and
incubated at 50°C for 3 h. A 10-µl volume of RNase A (2 mg/ml)
was added to the lysates, and the tubes were incubated for an
additional 1 h. This lysate was mixed well with 1 µl of ethidium
bromide (20 µg/ml), extracted once with an equal volume of
phenol-chloroform (1:1), and stored at 4°C after the addition of 20 µl of 1% low-melting-point agarose solution containing 10 mM EDTA
(pH 8.0). The samples were melted at 70°C and allowed to solidify
inside the well before electrophoresis was initiated.
Immunoblotting.
Cells to be analyzed were lysed in RIPA
buffer containing 10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1%
Nonidet P-40, 0.1% sodium dodecyl sulfate (SDS), and 1% deoxycholate.
Cell extracts (50-µg portions) were resolved on an SDS-containing
12% polyacrylamide gel, transferred to polyvinylidene difluoride nylon
membranes (Millipore, Bedford, Mass.), and probed with antibodies
specific to Bcl-2, Mcl-1, and Bax (all purchased from Santa Crutz
Biotechnology, Santa Crutz, Calif.) or
-tubulin (Amersham, Little
Chalfont, England). The membrane was then probed with horseradish
peroxidase-conjugated goat anti-mouse or goat anti-rabbit antibody. The
specific bands were visualized with an enhanced chemiluminescence
Western blot system (Amersham).
Northern blotting.
Total RNA was isolated from cultured
cells by a previously described method (25). A 20-µg
portion of total RNA was resolved on a 1% formaldehyde-agarose gel
and blotted onto a nitrocellulose filter by the standard procedure. The
blot was then probed sequentially with various
[
-32P]dCTP-labeled DNA fragments by the random-priming
method. After overnight hybridization at 42°C with standard buffer
containing 50% formamide, the blot was washed once in 2× SSC (1× SSC
is 0.15 M NaCl plus 0.015 M sodium citrate)-0.1% SDS and twice in
0.2× SSC-0.1% SDS at 55°C and subjected to either autoradiography
or direct quantitation with a PhosphorImager (Molecular Dynamics).
Determination of the Mcl-1 half-life.
To measure the
half-life (t1/2) of Mcl-1 in cells containing
GM-CSF, 107 TF-1 cells in the rapidly growing phase were
precultured for 30 min in 3 ml of methionine-free medium supplemented
with 0.5% dialyzed FBS and 10 ng of GM-CSF per ml to deplete
endogenous methionine. Pulse-labeling was initiated by adding 1 mCi of
[35S]Met (Amersham; 10 mCi/ml, >1,000Ci/mmol). After 15 min at 37°C, the cells were chased in growth medium containing 0.5%
FBS, 10 ng of GM-CSF per ml, and 10 mM methionine. At various times
after the chase, the cells were lysed in RIPA buffer and
immunoprecipitated with anti-Mcl-1 antibody. The immunoprecipitated
complexes were resolved on an SDS-containing 10% polyacrylamide gel
and visualized by fluorography. To measure the
t1/2 of Mcl-1 in cells containing no GM-CSF, the
same procedure was used but the cells were deprived of GM-CSF for
6 h prior to labeling and GM-CSF was omitted during the
pulse-labeling and chasing steps. This modified procedure was necessary
to ensure that only a minimal amount of GM-CSF was present during the
pulse-labeling step to stimulate the synthesis of Mcl-1 and that this
residual amount of cytokine could be thoroughly removed at the
subsequent chasing step.
[3H]thymidine incorporation assay.
Ba/F3
transfectants were normally maintained in medium with murine IL-3 as
described above. One day before the assay, they were seeded at a
density of 105/ml in medium containing mIL-3, hGM-CSF, or
no cytokine. To determine their mitogenic responses in these cytokines,
104 viable cells from each of these three populations were
individually seeded into the 96-well culture plate by using the same
medium in which these cells had been previously cultured for 24 h.
The mitogenic assay was initiated by the addition of 1 µCi of
[3H]thymidine (Amersham) to each well. After 20 min of
pulse-labeling, the cells were lysed and analyzed as previously
described (55). All assays were done in triplicate and
repeated three times.
Plasmids.
PCDNA-3/bcl-2, PCDNA-3/m-mcl-1, and
PCDNA-3/h-mcl-1 are mammalian expression vectors driving
bcl-2 and mouse and human mcl-1 cDNA,
respectively, under the control of cytomegalovirus promoters. PCDNA-3/bcl-2 was generated by PCR amplification of the coding region
of the bcl-2 cDNA (in the BK-KS-H-Bcl-2 plasmid provided by
Stanley J. Korsmeyer, Washington University School of Medicine, St.
Louis, Mo.) with the following two primers: sense, 5'
GCGAATTCGTTGGCCCCGTTGCTTTT 3'; antisense, 5'
GCGTCGACAGGCATGTTGACTTCACT 3'. The amplified fragments were
restricted with EcoRI and SalI and cloned into the EcoRI and XhoI sites of the pCDNA-3 vector
(Invitrogen). PCDNA-3/m-mcl-1 was constructed by subcloning the
EcoRI-XbaI fragment of the mouse mcl-1
cDNA in pBluescript vector (provided by Stanley J. Korsmeyer) into the
corresponding sites of the pCDNA-3 vector. The human mcl-1
cDNA encompassing the entire coding region (~1.1 kb) was synthesized
by reverse transcription-PCR amplification of mRNA isolated from TF-1
cells with the following two primers: sense, 5'
GCGGATCCACCATGTTTGGCCTCAAAAGA 3'; antisense,
5'GCGTCGACAGGCTATCTTATTAGATATGC 3' (designed
according to the published sequences) (19). Briefly, 1 µg of mRNA was reverse transcribed with recombinant Moloney murine
leukemia virus reverse transcriptase (GIBCO-BRL) and the antisense
primer listed above. The first-strand cDNA was then PCR amplified with
these two primers and the Advantage KlenTag polymerase mix
(Clontech). The PCR-amplified human mcl-1 cDNA fragment was
digested with BamHI and SalI and cloned into the BamHI and XhoI sites of the pCDNA-3 vector. Both
PCR-amplified bcl-2 and human mcl-1 cDNAs were
confirmed by DNA sequencing to be free from mutations that would
change the amino acid sequence of the encoded proteins. pUHD-mcl-1(S)
and pUHD-mcl-1(AS) are two tetracycline-regulated expression vectors
driving human mcl-1 cDNA in a sense or antisense
orientation, respectively. They were generated by inserting the human
mcl-1 cDNA in either direction into the EcoRI
site of the pUHD10-3 vector (8a).
Cloning of the 5'-flanking region of the murine mcl-1
gene.
A murine ES cell (129/Sv) genomic library (in Lambda FIX II
vector) was screened by the standard method (39a) with
murine mcl-1 cDNA as a probe. A single positive clone was
obtained from a screen of 2 × 105 recombinant phages.
Southern blot analysis with distinct parts of the cDNA revealed that a
2.8-kb HindIII-SacI fragment derived from
this phage insert (~14 kb [49b]) contains the 5' end of the coding
sequences. Sequencing of this DNA fragment confirmed that it contains
the first 399 bp of the open reading frame of the murine
mcl-1 cDNA (GenBank accession no. U35623 and our unpublished data) and 2,434 bp of the 5'-flanking sequences.
Primer extension analysis of transcriptional start sites.
The 5' end of the mcl-1 mRNA was determined by the standard
method as described previously (39a). Briefly, 40 µg of
total RNA (or 2 µg of mRNA) isolated from BaF/3 cells stimulated with mIL-3 for 1 h was hybridized with the 5'-end-labeled ATG-38 primer at 30°C for 12 h before Moloney murine leukemia virus reverse transcriptase was added to initiate the extension reaction. The resultant DNA fragment was resolved on a 6% denaturing polyacrylamide gel containing 7 M urea. The sequence of the ATG-38 primer is 5'
ATGACCGCGTTTCTCCGCAGGCCAAACATGGTCGGACG 3'.
Reporter plasmids and luciferase assay.
The mcl-1
genomic clone was digested with various restriction enzymes and the
resultant DNA fragments were subcloned by standard methods into the
multiple-cloning sites of the promoterless vector pGL-2-basic (Promega)
to generate the reporter constructs p(
2389/+10)mcl-luc, p(
1288/+10)mcl-luc, p(
564/+10)mcl-luc, p(
203/+10)mcl-luc,
p(
87/+10)mcl-luc, and p(
70/+10)mcl-luc. The numbers in parentheses
indicate the nucleotide position with respect to the transcriptional
initiation site shown in Fig. 5. pB-dl(
197/
69) was constructed by
deleting the internal region (
197/
69) from p(
1288/+10)mcl-luc.
During the construction of these reporter plasmids, some DNA fragments to be cloned were PCR amplified with appropriate primers and subcloned into pGL-2-basic. All plasmids constructed in this way were confirmed by sequencing to be free of base mutations in the amplified region. To
analyze the promoter activity of these reporter genes, BaF3 or 
wt
cells were transiently transfected with these plasmids by
electroporation with a Bio-Rad Gene Pulser II RF Module system set at
the following conditions: 300 V, 40 kHz, five bursts at 2 ms each, and
100% modulation. Electroporated cells were seeded in growth medium
with or without mIL-3 (or hGM-CSF). At 12 h after reseeding, the
cells were harvested and assayed for luciferase activity. A
cytomegalovirus-driven chloramphenicol acetyltransferase reporter gene
was cotransfected to correct for variations in transfection efficiency.
Transient transfection and detection of Bcl-2 or Mcl-1 expression
by flow cytometry.
Teo4, another line of TF-1 derivatives
expressing tTA for the Tet-off inducible system, was transiently
transfected with TRE (Tet-responsive element) vectors driving the
bcl-2 or mcl-1 cDNA in a sense or antisense
orientation by using a liposome-mediated gene transfer method. Briefly,
DNA to be transfected (2 µg of the DNA construct of interest plus
one-sixth the molar amount of green fluorescent protein (GFP)
expression vector) was gently mixed with 2.5 µl of DMRIE-C
(GIBCO-BRL, Gaithersburg, Md.) to form the DNA-lipid complex. After 30 min, the preformed complexes were added to 106 cells which
had been washed once with serum-free medium. Following a 4-h incubation
in serum-free medium containing 2 ng of GM-CSF per ml, transfected
cells were divided into two parts and each part was replaced with fresh
growth medium containing or not containing tetracycline (2 µg/ml). At
20 to 42 h after transfection, the cells were analyzed for the
expression of GFP and Mcl-1 (or Bcl-2) by flow cytometry. For this
experiment, transfected cells were washed twice with phosphate-buffered
saline (PBS) before being fixed with 4% paraformaldehyde for 15 min at
room temperature. After a brief wash with PBS, fixed cells were
permeabilized with 0.1% saponin for 15 min, washed once with PBS, and
allowed to interact with rabbit antiserum specific to Bcl-2 or Mcl-1
(Santa Cruz). After a 1-h incubation with primary antibody, the cells were washed three times with PBS plus 0.05% Tween 20 (PBST) and further incubated with biotin-conjugated goat anti-rabbit
immunoglobulin G (IgG) (Vector Laboratories) for a further 1 h.
After three more washes in PBST, the cells were incubated with
phycoerythrin-conjugated streptavidin (Jackson ImmunoResearch
Laboratories, West Grove, Pa.) for 30 min, washed three times with
PBST, and analyzed by flow cytometry with a Becton Dickinson FACScan as
specified by the manufacturer. For detection of cells expressing GFP,
cells were analyzed with the FL-1 channel (excitation, 488 nm;
emission, 530/30 nm). For Bcl-2 or Mcl-1 expression, cells were
analyzed with the FL-2 channel (excitation, 488 nm; emission, 585/42
nm). All incubation steps were carried out at room temperature, and all
antibodies were used at the dilutions recommended by the manufacturer.
Apoptosis detection by annexin-V staining.
Cells transiently
transfected with constructs of interest plus expression vectors
encoding GFP or a chimeric protein, CD16/CD7 (see below), were fixed in
2% paraformaldehyde at room temperature for 15 min. After being rinsed
with binding buffer (10 mM HEPES/NaOH [pH 7.4], 140 mM NaCl, 5 mM
CaCl2), fixed cells were incubated in the same buffer
containing biotin-conjugated annexin-V (Boehringer GmbH, Mannheim,
Germany) for another 20 min at room temperature. After several washes,
the annexin-V-bound cells were revealed by binding to Texas red
(Vector, Burlingame, Calif.)- or phycoerythrin-conjugated streptavidin
and analyzed by confocal microscopy (Zeiss) or flow cytometry,
respectively. In experiments in which CD16/CD7 was used as a
cotransfection marker, a monoclonal antibody recognizing the
extracellular domain of CD16 (MCA1193; Serotec) was included in the
staining procedure. Cells cotransfected with this surface marker were
further stained with fluorescein isothiocyanate-conjugated goat
anti-mouse IgG (Jackson ImmunoResearch Laboratories) and analyzed by
flow cytometry as described above. The expression vector encoding
CD16/CD7 fusion protein (the extracellular domain of the cell surface
marker CD16 fused to the transmembrane domain of CD7) was derived from
pEFCD16/7/Syk (27) by inserting a stop codon into the
MluI site immediately downstream of the CD7 coding region.
For measurement of apoptosis of nontransfected cells, the same staining
procedure was used except that the fixing step was omitted and the
annexin-V bound cells were quantified with CytoFluor 2350 fluorescence
measurement system (Millipore).
Nucleotide sequence accession number.
The nucleotide
sequence reported in this paper will appear in the GenBank database
under accession no. AF063886.
 |
RESULTS |
GM-CSF stimulates Mcl-1 expression at both the protein and mRNA
levels.
Both serum and GM-CSF are required for the long-term
growth of the human myeloid progenitor cell line TF-1. Upon depletion of GM-CSF from the normal growth medium, the viability of TF-1 decreased with time and cells underwent apoptosis (55).
However, if the cells were deprived of GM-CSF and subsequently placed
in medium containing a low concentration of serum (0.5%), their death rate was greatly increased and more consistent from experiment to
experiment when different batches of serum were used (data not shown).
This was probably because serum also provided some survival activity to
TF-1 cells and this survival activity varied among different batches of
serum. For the sake of consistency, in all cytokine depletion and
restimulation experiments carried out in this study, the cells were
placed in medium with 0.5% serum. Under the conditions used in a
standard depletion assay (Fig. 1A), the
DNA ladder was not prominent until approximately 40% of the cells had
lost their viability (~20 to 24 h after cytokine depletion) and
had undergone apoptosis (Fig. 1B). To investigate the role of Bcl-2
family proteins in this type of apoptosis, the expression patterns of
this protein family at various times after factor removal were
examined. In six independent experiments, we consistently observed that
the level of Mcl-1 decreased rapidly and significantly following
withdrawal of the survival factor from the culture medium (Fig. 1C).
Upon readdition of GM-CSF to the growth factor-starved cells, the level
of Mcl-1 protein was immediately increased (Fig. 1C, lanes 9 to 11). In
contrast, even after a 24-h depletion of growth factors, the levels of
other Bcl-2 family members such as Bcl-2, Bax (Fig. 1C), and
Bcl-xL (data not shown) were not significantly affected (a
less-than-twofold change). Furthermore, none of these three members
could be immediately reinduced by GM-CSF as in the case of Mcl-1
(lanes 9 to 11 and data not shown). Of interest, A1, another member of
this protein family previously shown to be induced by GM-CSF
(23c), was hardly detectable in these cells (data not
shown).

View larger version (38K):
[in this window]
[in a new window]

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 1.
Mcl-1 levels correlate with the survival of TF-1 cells.
(A) Growth and death curves of TF-1 cells. TF-1 cells were seeded at a
density of 105/ml in regular growth medium containing
GM-CSF. At various times after seeding, the viable-cell number was
determined by trypan blue exclusion. At 48 h after seeding, some
cells were washed to remove GM-CSF and replated into low-serum (0.5%)
medium without GM-CSF. The viable-cell number in this group was
determined at various times after replating. (B and C) Cytokine
depletion induces apoptosis in TF-1 cells. Half of the cells depleted
of cytokine as described for panel A were harvested after counting, and
their genomic DNA was analyzed by agarose gel electrophoresis. The
other half of the cells were harvested, and equal amounts (50 µg) of
their protein lysates were analyzed by immunoblotting for the
expression of Mcl-1 and other proteins as indicated in the figure (C,
lanes 1 to 7). Cells deprived of GM-CSF, placed in low-serum medium for
24 h, and restimulated with GM-CSF for 0.5, 1, 3, and 6 h
were also prepared and analyzed (lanes 8 to 11). The data shown here
are representative results from one of three independent experiments
with very similar patterns. The standard deviation of the viable-cell
number (A) is indicated by error bars. D1, D2, and D3 indicate cells at
24, 48 or 72 h, respectively, after the initial seeding in regular
growth medium containing GM-CSF.
|
|
To examine if the rapid change of Mcl-1 protein levels as a result of
the absence or presence of the survival factor was due to changes in
the expression of its mRNA, total RNA isolated from cells during the
actively growing phase, cells that had been depleted of survival
factors for various times, or factor-deprived cells that had been
restimulated by GM-CSF were analyzed by Northern blot analysis. As
shown in Fig. 2A, the 3.9-kb transcript
of mcl-1 mRNA quickly dropped to the baseline level within 3 to 6 h after growth factor removal (the 2.5-kb transcript is too
weak to be detectable in this figure). However, upon restimulation of
factor-deprived cells (depleted for 6 h) with GM-CSF only, the
mcl-1 mRNA was rapidly induced. Its induction was transient
and peaked at 1 h (ca. three- to fourfold induction for the 3.9-kb
transcript [Fig. 2A, lane 7]) posttreatment. The mcl-1
mRNA was still induced by GM-CSF in the presence of cycloheximide,
suggesting that de novo protein synthesis was not required for this
process (Fig. 2B, lane 4). This induction pattern was similar to that
of junB (Fig. 2), an immediate-early gene activated by
various growth factors (9, 14, 23). These results indicated
that mcl-1 is an immediate-early gene activated by the
GM-CSF signaling pathway.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 2.
GM-CSF treatment increases mcl-1 mRNA levels.
TF-1 cells treated under various conditions as described below were
lysed, and their total RNA was isolated and analyzed by Northern
blotting with an mcl-1-specific probe. The same blot was
also stripped and sequentially reprobed with probes specific to
junB and the glyceraldehyde-3-phosphate dehydrogenase gene
(G3PDH), respectively. (A) Lanes: 1, cells in logarithmic phase (L); 2 to 6, cells depleted of GM-CSF and serum for 3 to 24 h; 7 to 9, cells depleted of GM-CSF and serum for 6 h and restimulated with
GM-CSF for 1, 3, and 6 h, respectively. (B) Lanes: 1 and 2, same
treatment as described for lanes 3 and 7 of panel A, respectively; 3, cells depleted of GM-CSF and serum for 6 h and stimulated with 10 µg of cycloheximide (cx) per ml for 1 h; 4, same treatment as
for lane 3 but stimulated with GM-CSF and cycloheximide (1+cx) for
1 h.
|
|
Mcl-1 was reported to be a labile protein probably due to the presence
of PEST sequences (
54). We were curious to know if
depletion
of GM-CSF would further facilitate the degradation of
Mcl-1. To examine
this, the half-life of Mcl-1 in cells fed or
not fed with GM-CSF was
determined. In five independent experiments,
we consistently observed
that the half-life of Mcl-1 in cells
with GM-CSF was around 30 to 40 min (Fig.
3), which was similar
to the
previously reported half-life of ~1 h for the upper band
of Mcl-1
proteins (
54). (In the system we used, we were unable
to
detect the lower band, which was reported to have a longer
half-life of
~3 h.) The half-life of Mcl-1 in cells depleted of
GM-CSF was very
similar to that of cells in the presence of GM-CSF
(also ~30 to 40 min [Fig.
3]), suggesting that the Mcl-1 protein
levels affected by
the GM-CSF signaling pathway were regulated
mainly at the synthesis,
not the degradation, step.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 3.
Mcl-1 half-lives in cells cultured with or without
GM-CSF. TF-1 cells pulse-labeled with [35S]Met for 15 min
and chased with excess amounts of cold methionine were thoroughly
washed and reseeded in medium containing or not containing GM-CSF. (A)
At various times after reseeding, total-cell lysates were prepared and
immunoprecipitated with antibody specific to Mcl-1, and the
immunoprecipitated complexes were resolved on an SDS-containing 10%
polyacrylamide gel and visualized by fluorography. The Mcl-1-specific
bands were quantified with a PhosphorImager. (B) After normalization to
the amount of an unknown (Unk) protein whose levels remain constant
during experimental period, the level of Mcl-1 at each time point was
converted to the percentage of Mcl-1 level at the time zero point and
plotted to determine the half-lives.
|
|
Induction of mcl-1 requires the membrane-distal domain
of the receptor
subunit.
The
chain of the GM-CSF receptor
plays the major role in transducing many signals generated by the
activated receptor. We were interested in determining which domain of
the
chain was important for the induction of mcl-1 by
GM-CSF. To address this issue, mIL-3-dependent Ba/F3 cells were
engineered to express the hGM-CSF receptor
chain alone or in
combination with various C-terminal truncation mutants of the receptor
chain (Fig. 4A). This
heterologous system proved to be useful to study the hGM-CSF receptor
signaling pathway, because the introduction of the wild-type hGM-CSF
receptor into Ba/F3 cells resulted in rapid growth of these cells in
medium containing hGM-CSF but in only their usual general growth
properties in medium containing mIL-3 or without any cytokine
(40). As shown in Fig. 4B, while bcl-2 mRNA
levels in all Ba/F transfectants were very low and were not
significantly affected by mIL-3 or hGM-CSF (Fig. 4B), the regulation of
mcl-1 mRNA in these cells by mIL-3 or hGM-CSF was quite
discernible. mcl-1 mRNA was induced in all Ba/F3 derivatives
cultivated in medium containing mIL-3, which supports the long-term
growth of these cells. However, when these cells were cultivated in
medium containing hGM-CSF, they had differential responses. Only

wt (expressing wild-type hGM-CSF receptor
and
chains) and

755 (expressing
chain and
chain C-terminally deleted to
amino acid [aa] 756) cells retained the ability to induce
mcl-1 upon stimulation with hGM-CSF. The mcl-1
induction by hGM-CSF was abolished in cells expressing an
chain
alone (Ba/F
) or expressing
chain in combination with a
-chain
mutant C-terminally deleted up to either aa 574 (
573) or aa
454 (
453). This result suggests that mcl-1 induction
by hGM-CSF requires the membrane-distal region of the
chain
between aa 573 and 755, a domain that is also important for the
induction of other immediate-early genes such as jun, fos and myc (Fig. 4B). Of note, deletion of this
region resulted in differential effects on the anti-apoptotic and
mitogenic activities of the receptor. As shown in Fig. 4C and D, in
medium containing hGM-CSF, 
573 cells underwent apoptosis even
though they still retained partial mitogenic activity (~40 to
50% of the activity of the same cells in mIL-3) (Fig. 4E). To be
able to quantitatively compare the apoptotic response of

573 cells in medium containing mIL-3 or hGM-CSF or without any
factor, equal numbers of cells (2 × 106 in 10 ml)
were seeded in various culture media. At 24 h after seeding, the
numbers of viable and apoptotic cells were determined by trypan blue
and annexin-V binding assays, respectively. Under these conditions, we
always observed that cells seeded in mIL-3 could reach a density of
(7.4 ± 0.2) × 105/ml whereas cells in hGM-CSF or
without any factor reached only (2.0 ± 0.2) × 105
and (1.0 ± 0.1 × 105) per ml, respectively.
Although cells seeded under the last two conditions had different
amounts of viable cell numbers at the 24-h time point, they had similar
numbers of apoptotic cells as reflected by the fluorescent units of
annexin-V-bound cells (Fig. 4D) or by determination of the trypan
blue-positive populations (~2.5 × 105 per ml for
both). This result suggests that deletion of the
chain between aa
573 and 755 resulted in complete loss of the anti-apoptotic activity
while retaining partial mitogenic activity of the activated receptor.

View larger version (22K):
[in this window]
[in a new window]

View larger version (93K):
[in this window]
[in a new window]

View larger version (29K):
[in this window]
[in a new window]

View larger version (64K):
[in this window]
[in a new window]
|
FIG. 4.
Mcl-1 induction requires the membrane-distal domain of
the GM-CSF receptor chain. (A) Schematic representation of human
GM-CSF receptor mutants transfected into Ba/F3 cells. (B) Ba/F3 cells
expressing various receptor mutants were depleted of cytokine for
20 h before they were stimulated with mIL-3 or hGM-CSF. At various
times after stimulation (0.5 to 3 h), the cells were lysed and
their total RNA was analyzed by Northern blotting with specific probes
as indicated in the figure. (C) Equal numbers (2 × 106) of Ba/F3 cells expressing various GM-CSF receptor
mutants were seeded for 24 h in 10 ml of medium containing no
cytokine, mIL-3, or hGM-CSF, and then their genomic DNA was extracted
and analyzed by agarose gel electrophoresis (2% agarose). (D) Cells
treated as in panel C were stained with biotinylated annexin-V and
Texas red-conjugated streptavidin as described in Materials and
Methods. The positively stained (apoptotic) cells were quantified with
Cytofluor 2350. The fluorescence units of the annexin-V-bound cells are
plotted here to reflect the absolute numbers of apoptotic cells. ,
S; , mIL-3; , hGM-CSF. (E) Mitogenic activity of Ba/F3 cells
expressing various receptor mutants. Cells (104) cultured
in medium containing no cytokine (S), mIL-3 or hGM-CSF were
pulse-labeled with [3H]thymidine for 20 min and lysed,
and the incorporated counts were measured with a -counter.
|
|
Cytokine activates the mcl-1 gene promoter.
To
examine if the induction of mcl-1 mRNA by GM-CSF or IL-3
(Fig. 4B) was regulated at the transcriptional level, the 5'-flanking region of the murine mcl-1 gene was isolated (see Materials
and Methods) and sequenced (Fig. 5A).
Primer extension (Fig. 5B) and S1-mapping (data not shown) analyses
revealed that the transcriptional initiation site (TI) of this gene was
located 45 nucleotides upstream of the first ATG of the open reading
frame deduced from the murine mcl-1 cDNA. To examine if the
cloned 5'-flanking DNA fragment immediately upstream of the TI site
conferred any promoter activity, a luciferase reporter gene containing
sequences between
2389 and +10, p(
2389/+10)mcl-luc, was
analyzed. This reporter, when transfected into BaF/3 cells,
manifested some promoter activity compared to the promoterless parental
vector, pGL2-basic (Fig. 6B and C).
Addition of IL-3 further increased the promoter activity by
~threefold, which was similar to the fold increase at the mRNA level
as a result of GM-CSF (Fig. 2) or IL-3 (Fig. 4B) addition. To map the
promoter region that was responsible for cytokine inducibility, a
series of reporters harboring various regions of the promoter DNA were
analyzed (Fig. 6A). As shown in Fig. 6B and C, IL-3 inducibility requires the presence of the DNA region between
197 and
69. An
identical promoter region was mapped for the GM-CSF inducibility when
these deletion mutants were analyzed in 
wt cells (data not
shown). Taken together, these results suggest that cytokine induction
of mcl-1 mRNA is regulated mainly at the transcriptional level.

View larger version (66K):
[in this window]
[in a new window]

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 5.
Mapping of the TI site of the murine mcl-1
promoter. (A) Nucleotide sequence of the murine mcl-1 gene
promoter region. The numbering of the nucleotides is relative to the TI
site at +1. The restriction enzyme sites used for generating luciferase
reporter constructs are shown in italics. The SIF- and CRE-2-like
sequences (see text) are underlined. (B) Primer extension of RNA
isolated from Ba/F3 cells with the ATG-38 primer (see Materials and
Methods). Extension products from 2 µg of mRNA or from 40 µg of
total RNA are shown in lanes 3 and 4, respectively. Products of a
control reaction in which cellular RNA was replaced with 200 µg of
yeast tRNA are shown in lane 2. A sequencing reaction product from a
reaction performed with the ATG-38 primer was also loaded onto the same
denaturing gel to help assign the TI site. The DNA template used for
sequencing was the HindIII-SacI genomic
fragment as described in Materials and Methods.
|
|

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 6.
Cytokine activates the mcl-1 gene promoter.
(A) Schematic representation of luciferase reporter genes driven by
various regions of the mcl-1 promoter. (B) BaF/3 cells
transfected with various luciferase reporters as indicated were
stimulated with IL-3 or not stimulated, and the lysates were analyzed
for luciferase activity (in arbitrary units). Very similar results were
obtained from four independent experiments, and the data shown here are
from one representative assay. (C) The average fold induction
(mean ± standard deviation, n = 4) by IL-3 for
each construct analyzed in panel B. The luciferase activity generated
from the expression of pUHC13-3 (a luciferase reporter driven by the
minimal CMV promoter) was not affected by IL-3 and is included as a
negative control.
|
|
Mcl-1 plays a role in the survival activity of the activated GM-CSF
receptor.
As shown above, mcl-1 mRNA was induced only
in cells that could survive under that culture condition (i.e., all
cells in the presence of mIL-3 and 
wt and 
755 cells in the
presence of hGM-CSF). This result suggested that Mcl-1 may play a role
in the anti-apoptotic activity of the GM-CSF and IL-3 signaling
pathway. To examine this possibility, the following experiments were
performed. First, we examined if ectopic overexpression of Mcl-1 would
prevent TF-1 cells from undergoing apoptosis upon depletion of their
dependent cytokines. For this experiment, TF-1 cells conditionally
overexpressing Mcl-1 were generated by using the Tet-off inducible
system. Two independent clones (Mcl10-1 and Mcl10-2) were isolated, and
their Mcl-1 levels in the presence or absence of tetracycline were
analyzed by immunoblotting (Fig. 7A).
Upon removal of tetracycline (Fig. 7A, lanes 4 and 6), Mcl-1 was
induced approximately 2.5-fold in Mcl10-1 and 20-fold in Mcl10-2. When
deprived of GM-CSF, these cells still died but at a rate significantly
lower than under conditions where Mcl-1 was not overproduced (i.e.,
cultivated in the presence of tetracycline) (Fig. 7B). As more Mcl-1
was induced, more protection was observed. Although the Bcl-2 protein or mRNA levels did not fluctuate significantly with the GM-CSF and IL-3
signaling pathway, its ectopic overexpression still delayed factor
withdrawal-induced apoptosis in TF-1 cells (Fig. 7B).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 7.
Overexpression of Mcl-1 delays GM-CSF withdrawal-induced
apoptosis. (A) TF-1 cells stably overexpressing Mcl-1 under a Tet-off
system were established. The Mcl-1 and Bcl-2 levels in these cells
grown in medium with or without tetracycline were analyzed by
immunoblotting. TFtD1, control TF-1 cells expressing tTA only. Mcl10-1
and Mcl10-2, two single clones derived from TFtD1 that overexpressed
Mcl-1 in medium without tetracycline. A pool of TF-1 cells
constitutively overexpressing Bcl-2 (lane 8) or control vector (Neo,
lane 7) was also analyzed. (B) Death curves of TF-1 derivatives
cultured in medium with or without tetracycline (+ and ,
respectively). Cells grown to a density of 3 × 105/ml
were washed to remove GM-CSF, and the viable-cell numbers were
determined by trypan blue exclusion. The percent survival relative to
those seeded is plotted against days after GM-CSF removal. Cells
constitutively overexpressing Bcl-2 (TF/Bcl-2) or control vector
(TF/Neo) were also analyzed.
|
|
Next, we determined if a delay of apoptosis could also be observed in a
transient-transfection assay. To examine this, TF-1
cells were
transiently transfected with
mcl-1 or
bcl-2
expression
vector along with one-sixth the molar amount of a
GFP-expressing
construct. Although GFP-positive cells disappeared
slowly over
time in the transient-transfection assay, removal of GM-CSF
after
transfection significantly accelerated this process (Fig.
8B).
This was presumably due to an
increased rate of apoptosis of all
cells tested under this
cytokine-free condition, and the GFP fluorescence
tended to be lost in
the apoptotic cells. To test the effect of
Mcl-1 or Bcl-2 on cell death
rate measured by this transient-transfection
method, we examined
specifically how fast the cells transiently
expressing either of these
two proteins (identified by their coexpression
of GFP) would disappear
following GM-CSF withdrawal. As illustrated
in Fig.
8A, the
bcl-2 or
mcl-1 cDNA-transfected cells (GFP
positive)
indeed tended to express larger amounts of Bcl-2 or Mcl-1
proteins
than did nontransfected cells as measured by flow cytometry.
Under
the same conditions, the empty control vector did not have any
effect on the expression of these two proteins. In three independent
experiments, we consistently observed that cells transiently
overexpressing
Mcl-1 or Bcl-2 had a delayed rate of disappearance of
GFP-positive
cells (and therefore a delayed rate of apoptosis) after
transfected
cells were stripped of GM-CSF (Fig.
8B). We noticed,
however,
that the protection effect of Mcl-1 (10 to 20%) in this
transient-transfection
experiment (Fig.
8) was not as efficient as that
in the stable-cell-line
assay (Fig.
7), even though the former assay
usually yields higher
levels of protein expression than the latter one.
The exact mechanism
is unknown but could be due to differences in the
time point (24
to 30 h versus 2 to 3 days), the assay method (GFP
versus trypan
blue), and/or the amounts (a fraction versus all cells
overexpressing
Mcl-1) used in these two different systems.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 8.
TF-1 cells transiently overexpressing Mcl-1 or Bcl-2
delayed the disappearance of transfected cells (GFP marked) following
removal of GM-CSF. (A) Cells were transiently transfected with
pCDNA-3/h-mcl-1, pCDNA-3/m-mcl-1, pCDNA-3/bcl-2, or a control plasmid
along with one-sixth the molar amount of GFP vectors. At 15 h
after transfection, some cells were analyzed for their expression of
Mcl-1 or Bcl-2 by flow cytometry; others were depleted of GM-CSF. The
solid peaks indicate cells stained with control rabbit IgG, and the
open peaks indicate cells stained with Mcl-1 (upper and lower left
panels) or Bcl-2 antibody (upper and lower right panels). The open
peaks in gray lines indicated total transfected cells (nongated), and
black lines show the GFP positive populations. The transfection
efficiency was 1 to 3%. (B) At various times after GM-CSF removal, the
number of GFP positive cells in each transfectant was analyzed by flow
cytometry and plotted against hours relapsed. Cells transfected with
the control vector but placed in medium with GM-CSF (pCDNA-3+GM-CSF)
were included as a control. The GFP numbers at time zero were taken as
100%, and the numbers at subsequent time points were plotted as the
percentage relative to the initial numbers. This relative percentage
was designated the survival index. Data shown here are means of three
independent experiments.
|
|
To further demonstrate that Mcl-1 indeed played a role in the
anti-apoptotic activity of the GM-CSF signaling pathway, experiments
were designed to reduce the endogenous amount of Mcl-1 and to
examine
its effect on the survival of affected cells. Our initial
attempt was
to establish a Tet-off inducible line in which the
antisense
mcl-1 cDNA could be induced in the absence of tetracycline.
However, after several rounds of stable-cell-line selection, none
of
the clones that survived drug selection expressed antisense
mcl-1 (data not shown). This was probably due to some leaky
expression
of the cytotoxic antisense
mcl-1 in the presence
of tetracycline
(see below). We then performed transient-transfection
assays (Fig.
9) to
investigate this issue. In this experiment, the TeO4 cells
(another
TF-1 derivative stably overexpressing tTA for the Tet-regulated
system)
were transfected with a Tet-operator-controlled expression
vector
driving
mcl-1 cDNA in a sense or antisense orientation.
To
mark the transfected cells, a vector driving the expression
of GFP (at
one-sixth the molar amount) was again cotransfected.
After
transfection, half of the cells were cultured in complete
medium
(containing GM-CSF) with tetracycline and half were cultured
in the
same medium without tetracycline. The Mcl-1 protein levels
and the
number of GFP-positive cells in each case were measured
by flow
cytometry 20 or 42 h after transfection, respectively.
(Examination of the protein level at the early time point [20
h] was
necessary, because cells transfected with the antisense
vector tended
to die and lose GFP fluorescence at later time points
[see below].)
As illustrated in Fig.
9A, in the presence of tetracycline
the
endogenous Mcl-1 levels were slightly (10 to 15%) affected
by the
transfected DNA, a result probably due to some leaky expression
of
these constructs. However, in its absence, the endogenous Mcl-1
levels
were significantly affected. The sense construct tended
to express more
Mcl-1 protein (44% ± 3% of GFP-positive cells
expressed more
proteins than did the nongated controls), whereas
the antisense vector
tended to decrease the endogenous protein
level (31% ± 3% of
GFP-positive cells expressed less protein than
did the nongated
controls). None of these conditions affected
the expression of the
endogenous Bcl-2 proteins (Fig.
9B).

View larger version (52K):
[in this window]
[in a new window]

View larger version (85K):
[in this window]
[in a new window]
|
FIG. 9.
The Mcl-1 antisense construct induces apoptosis of TF-1
cells. (A and B) Flow cytometric analysis of Mcl-1 (A) or Bcl-2 (B)
levels in cells transfected with various vectors. TeO4 cells
transiently transfected with control vector, pUHD-mcl-1(S), or
pUHD-mcl-1(AS) along with the GFP expression vector as described in
Materials and Methods were treated with tetracycline for 20 h or
not treated. At this point, some cells were fixed and analyzed for
Mcl-1 or Bcl-2 expression by flow cytometry. For each transfection
experiment, a total of 5,000 cells (gated for GFP+ or
nongated) were analyzed. (C) The Mcl-1 antisense construct tended to
overcome the survival activity of GM-CSF and induce apoptosis of TF-1
cells. As described for panel A, cells that remained GFP positive at
the 42-h time point were stained with annexin-V and assessed for their
apoptotic status. Annexin-V-positive (biotin-labeled) cells were
recognized by Texas red-conjugated streptavidin and visualized by
confocal microscopy. For all conditions, two different views are shown
(views 1 and 2). For each panel, the upper left two images (A1, A2, E1,
E2, I1, I2, M1, M2, Q1, Q2, S1, and S2) are transfected cells viewed
under phase contrast; the upper right two views are the corresponding
field that showed the GFP-positive cells (B1, B2, F1, F2, J1, J2, N1,
N2, R1, R2, T1, and T2); the lower left two views (C1, C2, G1, G2, K1,
K2, O1, O2, U1, U2, W1, and W2) are the same field that showed the
annexin-V-positive cells (red); and the lower right two views (D1, D2,
H1, H2, L1, L2, P1, P2, V1, V2, X1, and X2) are the superimposed
results of the two fluorescent images. Yellow images are cells that
were doubly positive for GFP and annexin-V. Magnification, ×308.
|
|
In three independent experiments (Table
1), we consistently observed that cells
transfected with control vector and cultured
in medium without
tetracycline tended to retain slightly more
GFP-positive cells than did
the same transfected cells cultured
in medium containing tetracycline
(average increase of 5.1% ±
2.0%). If the cells were transfected
with Mcl-1 sense vector,
the number of GFP-positive cells in medium
without tetracycline
was further increased (average increase of 10.2% ± 1.3%). In contrast,
when cells were transfected with Mcl-1
antisense vector, a significant
loss of GFP-positive cells was observed
upon removal of tetracycline
(average decrease of 20.6% ± 2.8%).
Based on the observation that
GFP-positive cells gradually lost GFP
fluorescence upon GM-CSF
withdrawal (Fig.
8B), this lost fraction (from
GFP-positive to
GFP-negative cells) specifically seen in cells
transfected with
the antisense vector most probably represented those
cells whose
Mcl-1 protein levels were effectively reduced and had
undergone
apoptosis to the point at which the GFP fluorescence was lost
(some of these cells, annexin-V positive but GFP negative, are
shown in
Fig.
9C, X2). On the other hand, under the same conditions,
the
transfected populations that remained identifiable by their
GFP
fluorescence tended to have more apoptotic cells than did
those from
cells transfected with control or sense vectors, as
revealed by
annexin-V staining and viewed under a confocal microscope
(Fig.
9C, X1
and X2). This double-positive (GFP-positive and annexin-V-positive)
population increased (~12% [see Table
2]) in cells transfected
with the antisense vector under induced conditions (lacking
tetracycline)
probably represented transfected cells that were dying
but at
the early stage of apoptosis when GFP fluorescence remained
detectable.
To quantify the percentage of these double-positive
populations,
an identical experiment to that described in Fig.
9 but
replacing
GFP DNA with an expression vector driving the synthesis of a
chimeric
protein expressed on the cell surface (CD16/CD7 [see
Materials
and Methods]) was carried out. Cotransfection with GFP or
CD16/CD7
gave very similar results in terms of loss of transfected
markers
upon apoptosis (data not shown). However, CD16/CD7, after being
stained with primary and fluorescein isothiocyanate-conjugated
secondary antibodies, gave a much better signal than GFP did in
the
FL-1 channel of the flow cytometer. Table
2 shows that transfection
with the vector
control generated a background level (~12%) of
apoptotic cells
(double positive for annexin-V and CD16) irrespective
of the presence
or absence of tetracycline in the culture medium,
a result probably due
to the toxicity of DMRIE-C used in the assay.
A similar case was also
observed in experiments with the
mcl-1 sense vector. In
contrast, introduction of the antisense vector
under induced conditions
(without tetracycline) significantly
increased the percentage of this
double-positive population that
was at the early stage of apoptosis
(average increase of 11.9%
± 6.1%). Taken together, these results
and those in Fig.
9 and
Table
1 clearly indicate that down-regulation
of Mcl-1 by antisense
constructs at least partially overcame the
survival activity of
GM-CSF and induced apoptosis of dependent cells.
 |
DISCUSSION |
mcl-1 was originally identified as an early gene
induced during differentiation of ML-1 myeloid leukemia cells
(19). Although overexpression of the Mcl-1 protein can
protect against apoptosis triggered by various death inducers (38,
58), its physiological function is still unclear. In this report,
we show that mcl-1 is an immediate-early gene activated by
the GM-CSF signaling pathway. Furthermore, unlike other members of the
Bcl-2 family protein, the Mcl-1 protein level was tightly regulated by
this survival cytokine in TF-1 myeloid progenitor cells. Ectopic
overexpression of Mcl-1 delayed the apoptosis of TF-1 cells triggered
by GM-CSF withdrawal, whereas antisense blocking of endogenous Mcl-1
overcame, at least partially, the protective effect of GM-CSF and
promoted the apoptosis of TF-1 cells. These results strongly suggest
that Mcl-1 plays a role in the survival function of the GM-CSF
signaling pathway.
Several lines of evidence suggest that Mcl-1, Bcl-2, and possibly other
members of this protein family together mediate the anti-apoptotic
function of IL-3 and GM-CSF. (i) Overexpression of Bcl-2 or Mcl-1 alone
in the cell system used here delayed but did not completely prevent
GM-CSF withdrawal-induced apoptosis. (ii) Zha et al. (57)
reported that an IL-3-activated signal led to phosphorylation of Bad,
which was then sequestered in the cytosol bound to 14-3-3. The
serine-phosphorylated Bad failed to bind to Bcl-xL and
therefore could not promote cell death. (iii) GM-CSF activated the
expression of A1, whose overexpression was reported to retard cell
death elicited by IL-3 withdrawal (24). (iv) Overexpression
of Bax or Bak accelerated IL-3 removal-induced cell death (4, 15,
33). (v) the Bcl-xL mRNA levels were recently shown
to be affected by IL-3 in bone marrow-derived BaF-3 cells
(23b). Since the Bcl-2 protein family is known to function by forming a homodimer or heterodimer with its relatives (reviewed in
reference 6), an IL-3- or GM-CSF-activated signal,
with its effect on the induction of some members (e.g., Mcl-1 and A1) and on posttranslational modification of other members (e.g., Bcl-2 and
Bad), will certainly change the ratios of complexes that prevent or
promote cell death. Alternatively, upon cytokine withdrawal from cells
like TF-1 cells, the rapid degradation of Mcl-1 could again shift the
equilibrium toward the formation of complexes that promote cell death.
The short half-life of Mcl-1, as well as its being an immediate-early
gene product, supports the notion that Mcl-1 plays an important role in
the IL-3- or GM-CSF-regulated cell death pathway. Since overexpression
of Mcl-1 to a level that is comparable to (e.g., in Mcl10-1) or even
higher than (e.g., in Mcl10-2) that in GM-CSF-stimulated cells alone did not completely prevent TF-1 cells from undergoing
factor-withdrawal-induced apoptosis, some other signals activated upon
IL-3 or GM-CSF binding to their receptors must also be necessary for
the survival function of these cytokines. These extra signals may
include signals that lead to the posttranslational modification of
Mcl-1 protein itself (three noncharacterized forms of proteins have
been observed [54]), signals that lead to the
activation of some other Bcl-2 family proteins (as described above),
and possibly signals that lead to activation of other, yet to be
identified IL-3- or GM-CSF-regulated genes. Taken together, all these
possibilities suggest that Mcl-1 is one important component of the
GM-CSF viability response.
Bcl-2 and Bcl-xL can form a heterodimer with Bax (33a,
41, 42, 58). In yeast two-hybrid systems, Mcl-1 also interacts with Bcl-2 and Bcl-xL at a much lower affinity than with
Bax (41). However, after many attempts, we found no evidence
that these interactions occurred in mammalian cells or that Mcl-1
existed as a homodimer (33a). It has been reported that the
ratio of Bcl-2 to Bax determines the survival or death of IL-3-depleted FL5.12 cells (33). It is possible that Mcl-1 utilizes a
mechanism similar to that of Bcl-2 to antagonize a death signal. Mcl-1
has a half-life of ~30 to 40 min irrespective of the presence or
absence of GM-CSF. When dependent cells are deprived of GM-CSF, the
synthesis of Mcl-1 is immediately interrupted. The Mcl-1 molecule that
has been synthesized, due to its short half-life, quickly degrades. The
shortage of Mcl-1 could lessen the possibility of the formation of an
Mcl-1-Bax heterodimer, which would promote the formation of a Bax-Bax
homodimer and induce cell death. More experiments are required to check
the accuracy of this possible scenario.
The ligand-conjugated GM-CSF receptor is known to activate many
downstream signaling molecules (10, 13, 34, 35, 39, 40). We
were interested in knowing which part of the activated receptor is
responsible for the induction of Mcl-1. From characterization of Ba/F3
cells harboring various C-terminally truncated mutants of the GM-CSF
receptor, we observed that induction of Mcl-1 required the
membrane-distal region of the receptor
chain (aa 573 to 755). This
region of the receptor, according to published results (40),
is likely to be important for the activation of the Ras, Raf, MAP, and
p70 S6 kinases and phosphoinositide 3-kinase. Several studies have
shown that the activation of these signaling molecules is important for
the survival activity of various growth factors (1, 16, 22, 26,
52). It is possible that induction of Mcl-1 synthesis is one
result of these survival signals activated after GM-CSF binding to its
own receptor. By promoter deletion analysis, we found that the upstream
region between positions
197 and
69 is required for cytokine
induction of the mcl-1 gene. This region of the promoter
contains DNA binding sites similar to the consensus sequences
recognized by SIF and CRE-2 binding proteins (11, 49a). The
SIF binding site is important for GM-CSF activation of the
c-fos promoter (36a). More experiments are required to delineate which transcriptional factor is responsible for
IL-3 or GM-CSF activation of the mcl-1 gene and how the
activity of this transcriptional factor is modulated by the
membrane-distal region of the
chain.
The anti-apoptotic activity of 
573 cells was completely lost in
medium containing hGM-CSF, whereas the mitogenic response of these
cells under the same condition was partially impaired. This result
suggests that the membrane-distal region of the receptor
chain also
plays a role in the mitogenic response and that the receptor-activated
mitogenic and anti-apoptotic signaling pathways may not be completely
independent as previously suggested (16). As in 
573
cells, the induction of Mcl-1 by hGM-CSF was abolished. This may be the
result of the following two likely explanations. First, Mcl-1 may play
a partial role in the mitogenic response of the receptor. This is based
on the observation that the partial loss (~40 to 50%) of mitogenesis
of 
573 cells in medium containing GM-CSF correlates with the loss
of Mcl-1 expression in these cells. Second, Mcl-1 may not play any role
in mitogenesis. This possibility is based on the fact that the
induction of several other genes, such as c-jun,
c-fos, and c-myc, is also lost in 
573
cells. It is possible that the partial loss of mitogenic ability of

573 cells in medium containing hGM-CSF is simply the result of
loss of expression of these three and possibly other, yet to be
identified genes. More experiments will be necessary to differentiate
these two possibilities.
During TPA-induced differentiation of ML-1 human leukemia cells, Mcl-1
is rapidly induced within 3 h of treatment, and its level may
gradually decline thereafter to a baseline level upon completion of
differentiation (54). We also found that Mcl-1 levels
increased in TPA-induced differentiating TF-1 cells but decreased
dramatically in TPA-induced apoptotic cells (data not shown). While
these results suggest that Mcl-1 plays an important role in myeloid
cell differentiation, its exact role during this process is unclear.
Fairbairn et al. (5) reported that overexpression of Bcl-2
suppressed IL-3 withdrawal-induced apoptosis of a multipotent hematopoietic cell line, which allowed differentiation and development of these cells in the absence of added growth factors. It is possible that Mcl-1 plays a role similar to Bcl-2 or other survival factors during hematopoietic cell differentiation. That is, its major role in
the differentiation process is to suppress apoptosis and allow the
intrinsically determined differentiation program to proceed
(5).
Mice deficient in Bcl-2 or Bcl-x have different phenotypes.
Bcl-2-deficient mice undergo normal embryonic development but have
fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair (31, 49). Bcl-x-deficient mice show massive cell death of immature hematopoietic cells and neurons (30). These
results suggest that although both Bcl-2 and Bcl-xL have
anti-apoptotic activities, their effects vary in different tissues and
during different developmental stages. Following the same line of
reasoning, Mcl-1 may exert another type of regulation of apoptosis,
since it is widely distributed in various tissues and cell types and its expression profile differs slightly from that of Bcl-2 and Bcl-xL (20, 21, 54). Generation of Mcl-1
knockout mice may help us understand the real role of Mcl-1 in the
biological system.
 |
ACKNOWLEDGMENTS |
We thank R. H. Chen and Douglas Platt for their critical
reviewing and editing of the manuscript.
This work was supported in part by an intramural fund from Academia
Sinica and by grants NSC-83-0203-B-001-002 and NSC-85-2311-B-001-043 from the National Science Council of Taiwan to H.-F. Yang-Yen and by
grant DOH85-HR507 from the Department of Health to Chen-Kung Chou.
J.-R. Chao and J.-M. Wang contributed equally to this work.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Institute of
Molecular Biology, Academia Sinica, 128 Yen-Jiou Yuan Rd. Sec. 2, NangKang, Taipei 11529, Taiwan, Republic of China. Phone:
886-2-2789-9228. Fax: 886-2-2782-6085. E-mail:
IMBYY{at}ccvax.sinica.edu.tw.
 |
REFERENCES |
| 1.
|
Ahmed, N. N.,
L. Grimes,
A. Bellacosa,
T. O. Chan, and P. N. Tsichlis.
1997.
Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase.
Proc. Natl. Acad. Sci. USA
94:3627-3632[Abstract/Free Full Text].
|
| 2.
|
Arai, K.,
F. Lee,
A. Miyajima,
N. Arai, and T. Yokota.
1990.
Cytokines: coordinators of immune and inflammatory responses.
Annu. Rev. Biochem.
59:783-836[Medline].
|
| 3.
|
Boise, L. H.,
M. Gonzalez-Garcia,
C. E. Postema,
L. Ding,
T. Lindsen,
L. A. Turka,
X. Mao,
G. Nunez, and C. B. Thompson.
1993.
Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.
Cell
74:597-608[Medline].
|
| 4.
|
Chittenden, T.,
E. A. Harrington,
R. O'Connor,
C. Flemington,
R. J. Lutz,
G. I. Evan, and B. C. Guild.
1995.
Induction of apoptosis by the Bcl-2 homologue Bak.
Nature
374:733-736[Medline].
|
| 5.
|
Fairbairn, L. J.,
G. J. Cowling,
B. M. Reipert, and T. M. Dexter.
1993.
Suppression of apoptosis allows differentiation and development of a multipotent hemopoietic cell line in the absence of added growth factors.
Cell
74:823-832[Medline].
|
| 6.
|
Farrow, S. N., and R. Brown.
1996.
New members of the Bcl-2 family and their protein partners.
Curr. Opin. Genet. Dev.
6:45-49[Medline].
|
| 7.
|
Farrow, S. N.,
J. H. M. White,
I. Martinou,
T. Raven,
K. T. Pun,
C. J. Grinham,
J. C. Martinou, and R. Brown.
1995.
Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K.
Nature
374:731-733[Medline].
|
| 8.
|
Garcia, I.,
I. Martinou,
Y. Tsujimoto, and J. C. Martinou.
1992.
Prevention of programmed cell death of sympathetic neurons by the Bcl-2 proto-oncogene.
Science
258:304-304[Abstract/Free Full Text].
|
| 8a.
|
Gossen, M., and H. Bujard.
1992.
Tight control of gene expression in mammalian cells by tetracycline responsive promoters.
Proc. Natl. Acad. Sci. USA
89:5547-5551[Abstract/Free Full Text].
|
| 9.
|
Greenberg, M. E., and E. B. Ziff.
1984.
Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene.
Nature
311:433-438[Medline].
|
| 10.
|
Hanazono, Y.,
S. Chiba,
K. Sasaki,
H. Mano,
A. Miyajima,
K. Arai,
Y. Yazaki, and H. Hirai.
1993.
c-fps/fes protein-tyrosine kinase is implicated in a signaling pathway triggered by granulocyte-macrophage colony-stimulating factor and interleukin-3.
EMBO J.
12:1641-1646[Medline].
|
| 11.
|
Hyman, S. E.,
M. Comb,
Y.-S. Lin,
J. Pearlberg,
M. R. Green, and H. M. Goodman.
1988.
A common trans-acting factor is involved in transcriptional regulation of neurotransmitter genes by cyclic AMP.
Mol. Cell. Biol.
8:4225-4233[Abstract/Free Full Text].
|
| 12.
|
Ihle, J. N., and I. M. Kerr.
1995.
Jaks and Stats in signaling by the cytokine receptor superfamily.
Trends Genet.
11:69-74[Medline].
|
| 13.
|
Kanakura, Y.,
B. Druker,
J. Dicarlo,
S. A. Cannistra, and J. D. Griffin.
1991.
Phorbol 12-myristate 13-acetate inhibits granulocyte-macrophage colony stimulating factor-induced protein tyrosine phosphorylation in a human factor-dependent hematopoietic cell line.
J. Biol. Chem.
266:490-495[Abstract/Free Full Text].
|
| 14.
|
Kelly, K.,
B. H. Cochran,
C. D. Stiles, and P. Leder.
1983.
Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor.
Cell
35:603-610[Medline].
|
| 15.
|
Kiefer, M. C.,
M. J. Brauer,
V. C. Powers,
L. L. Wu,
S. R. Umansky,
D. Tomei, and P. J. Barr.
1995.
Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak.
Nature
374:736-739[Medline].
|
| 16.
|
Kinoshita, T.,
T. Yokota,
K. Arai, and A. Miyajima.
1995.
Suppression of apoptotic death in hematopoietic cells by signalling through the IL-3/GM-CSF receptors.
EMBO J.
14:266-275[Medline].
|
| 17.
|
Kitamura, T.,
T. Tange,
T. Terasawa,
S. Chiba,
T. Kuwaki,
K. Miyagawa,
Y. F. Piao,
K. Miyazono,
A. Urabe, and F. Takaku.
1989.
Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin.
J. Cell. Physiol.
140:323-334[Medline].
|
| 18.
|
Korsmeyer, S. J.
1995.
Regulators of cell death.
Trends Genet.
11:101-105[Medline].
|
| 19.
|
Kozopas, K. M.,
T. Yang,
H. L. Buchan,
P. Zhou, and R. W. Craig.
1993.
Mcl-1, a gene expressed in programmed myeloid cell differentiation has sequence similarity to Bcl2.
Proc. Natl. Acad. Sci. USA
90:3516-3520[Abstract/Free Full Text].
|
| 20.
|
Krajewski, S.,
S. Bodrug,
M. Krajewska,
A. Shabaik,
R. Gascoyne,
K. Berean, and J. C. Reed.
1995.
Immunohistochemical analysis of Mcl-1 protein in human tissues: differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo.
Am. J. Pathol.
146:1309-1319[Abstract].
|
| 21.
|
Krajewski, S.,
M. Krajewski,
A. Shabaik,
H. G. Wang,
S. Irie,
L. Fong, and J. C. Reed.
1994.
Immunohistochemical analysis of in vivo patterns of Bcl-X expression.
Cancer Res.
54:5501-5507[Abstract/Free Full Text].
|
| 22.
|
Kulik, G.,
A. Klippel, and M. J. Weber.
1997.
Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol-3-kinase, and Akt.
Mol. Cell. Biol.
17:1595-1606[Abstract].
|
| 23.
|
Lamph, W. W.,
P. Wamsley,
P. Sassone-Corsi, and I. M. Verma.
1988.
Induction of proto-oncogene Jun/AP-1 by serum and TPA.
Nature
334:629-631[Medline].
|
| 23a.
| Lee, S.-F., and J. J.-Y.
Yen. Unpublished data.
|
| 23b.
|
Leverrier, Y.,
J. Thomas,
G. R. Perkins,
M. Mangeney,
M. K. L. Collins, and J. Marvel.
1997.
In bone marrow derived Baf-3 cells, inhibition of apoptosis by IL-3 is mediated by two independent pathways.
Oncogene
14:425-430[Medline].
|
| 23c.
|
Lin, E. Y.,
A. Orlofsky,
M. S. Berger, and M. M. Prystowsky.
1993.
Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2.
J. Immunol.
151:1979-1988[Abstract].
|
| 24.
|
Lin, E. Y.,
A. Orlofsky,
H. G. Wang,
J. C. Reed, and M. B. Prystowsky.
1996.
A1, a Bcl-2 family member, prolongs cell survival and permits myeloid differentiation.
Blood
87:983-992[Abstract/Free Full Text].
|
| 25.
|
Liu, J.-J.,
J. R. Chao,
M. C. Jiang,
S. Y. Ng,
J. J. Yen, and H. F. Yang-Yen.
1995.
Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells.
Mol. Cell. Biol.
15:3654-3663[Abstract].
|
| 26.
|
Minshall, C.,
S. Arkins,
G. G. Freund, and K. W. Kelley.
1996.
Requirement for phosphatidylinositol 3'-kinase to protect hemopoietic progenitors against apoptosis depends upon the extracellular survival factor.
J. Immunol.
156:939-947[Abstract].
|
| 27.
|
Minami, Y.,
Y. Nakagawa,
A. Kawahara,
T. Miyazaki,
K. Sada,
H. Yamamura, and T. Taniguchi.
1995.
Protein tyrosine kinase syk is associated with and activated by the IL-2 receptor: possible link with the c-myc induction pathway.
Immunity
2:89-100[Medline].
|
| 28.
|
Miyajima, A.,
T. Kitamura,
N. Harada,
T. Yokota, and K. Arai.
1992.
Cytokine receptors and signal transduction.
Annu. Rev. Immunol.
10:295-331[Medline].
|
| 29.
|
Morgenstern, J. P., and H. Land.
1990.
Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line.
Nucleic Acids Res.
18:3587-3596[Abstract/Free Full Text].
|
| 30.
|
Motoyama, N.,
F. Wang,
K. A. Roth,
H. Sawa,
K. I. Nakayama,
K. Nakayama,
I. Negishi,
S. Senju,
Q. Zhang,
S. Fujii, and D. Y. Loh.
1995.
Massive cell death of immature haematopoietic cells and neurons in Bcl-x-deficient mice.
Science
267:1506-1509[Abstract/Free Full Text].
|
| 31.
|
Nakayama, K.-I.,
K. Nakayama,
I. Negishi,
K. Kuida,
Y. Shinkai,
M. C. Louie,
L. E. Fields,
P. J. Lucas,
V. Stewart,
F. W. Art, and D. Y. Loh.
1993.
Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice.
Science
261:1584-1588[Abstract/Free Full Text].
|
| 32.
|
Nunez, G.,
L. London,
D. Hockenbery,
M. Alexander,
J. P. McKearn, and S. J. Korsmeyer.
1990.
Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines.
J. Immunol.
144:3602-3610[Abstract].
|
| 33.
|
Oltvai, Z. N.,
C. L. Milliman, and S. J. Korsmeyer.
1993.
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.
Cell
74:609-619[Medline].
|
| 33a.
| Peng, H.-W., and H.-F. Yang-Yen.
Unpublished results.
|
| 34.
|
Pratt, J. C.,
M. Weiss,
C. A. Sieff,
S. E. Shoelson,
S. J. Burakoff, and K. S. Ravichandran.
1996.
Evidence for a physical association between the Shc-PTB domain and the c chain of the granulocyte-macrophage colony-stimulating factor receptor.
J. Biol. Chem.
271:12137-12140[Abstract/Free Full Text].
|
| 35.
|
Quelle, F. W.,
N. Sato,
B. A. Witthuhn,
R. C. Inhorn,
M. Eder,
A. Miyajima,
J. D. Griffin, and J. N. Ihle.
1994.
Jak2 associates with the c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region.
Mol. Cell. Biol.
14:4335-4341[Abstract/Free Full Text].
|
| 36.
|
Raff, M. C.,
B. A. Barres,
J. F. Burne,
H. S. Coles,
Y. Ishizaki, and M. D. Jacobson.
1993.
Programmed cell death and the control of cell survival: lessons from the nervous system.
Science
262:695-700[Abstract/Free Full Text].
|
| 36a.
|
Rajotte, D.,
H. B. Sadowski,
A. Haman,
K. Gopalbhai,
S. Meloche,
L. Liu,
G. Krystal, and T. Hoang.
1996.
Contribution of both STAT and SRF/TCF to c-fas promoter activation by granulocyte-macrophage colony-stimulating factor.
Blood
88:2906-2916[Abstract/Free Full Text].
|
| 37.
|
Reed, J. C.
1997.
Double identity for proteins of the Bcl-2 family.
Nature
387:773-776[Medline].
|
| 38.
|
Reynolds, J. E.,
T. Yang,
L. Qian,
J. D. Jenkinson,
P. Zhou,
A. Eastman, and R. W. Craig.
1994.
Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells.
Cancer Res.
54:6348-6352[Abstract/Free Full Text].
|
| 39.
|
Sakamaki, K.,
I. Miyajima,
T. Kitamura, and A. Miyajima.
1992.
Critical cytoplasmic domains of the common b subunit of the human GM-CSF, IL-3 and IL-5 receptors for growth signal transduction and tyrosine phosphorylation.
EMBO J.
11:3541-3549[Medline].
|
| 39a.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 40.
|
Sato, N.,
K. Sakamaki,
N. Terada,
K. Arai, and A. Miyajima.
1993.
Signal transduction by the high-affinity GM-CSF receptor: two distinct cytoplasmic regions of the common beta subunit responsible for different signaling.
EMBO J.
12:4181-4189[Medline].
|
| 41.
|
Sato, T.,
M. Hanata,
S. Bodrug,
S. Irie,
N. Iwama,
L. H. Boise,
C. B. Thompson,
E. Golemis,
L. Fong,
H. G. Wang, and J. C. Reed.
1994.
Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system.
Proc. Natl. Acad. Sci. USA
91:9238-9242[Abstract/Free Full Text].
|
| 42.
|
Sedlak, T. W.,
Z. N. Oltvai,
E. Yang,
K. Wang,
L. H. Boise,
C. B. Thompson, and S. J. Korsmeyer.
1995.
Multiple Bcl-2 family members demonstrate selective dimerizations with Bax.
Proc. Natl. Acad. Sci. USA
92:7834-7838[Abstract/Free Full Text].
|
| 43.
|
Sentman, C. L.,
J. R. Shutter,
D. Hockenbery,
O. Kanagawa, and S. J. Korsmeyer.
1991.
Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes.
Cell
67:879-888[Medline].
|
| 44.
|
Strasser, A.,
A. W. Harris, and S. Cory.
1991.
Bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship.
Cell
67:889-899[Medline].
|
| 45.
|
Steller, H.
1995.
Mechanisms and genes of cellular suicide.
Science
267:1445-1449[Abstract/Free Full Text].
|
| 46.
|
Thompson, C. B.
1995.
Apoptosis in the pathogenesis and treatment of disease.
Science
267:1456-1462[Abstract/Free Full Text].
|
| 47.
|
Tsujimoto, Y., and C. M. Croce.
1986.
Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma.
Proc. Natl. Acad. Sci. USA
83:5214-5218[Abstract/Free Full Text].
|
| 48.
|
Vaux, D. L.,
S. Cory, and J. M. Adams.
1988.
Bcl-2 promotes the survival of haemopoietic cells and cooperates with c-myc to immortalize pre-B cells.
Nature
335:440-442[Medline].
|
| 49.
|
Veis, D. J.,
C. M. Sorenson,
J. R. Shutter, and S. J. Korsmeyer.
1993.
Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair.
Cell
75:229-240[Medline].
|
| 49a.
|
Wagner, B. J.,
T. E. Hayes,
C. J. Hoban, and B. H. Cochran.
1990.
The SIF binding element confers sis/PDGF inducibility onto the c-fas promoter.
EMBO J.
9:4477-4484[Medline].
|
| 40b.
| Wang, J.-M., and H.-F. Yang-Yen. Unpublished
results.
|
| 50.
|
Williams, G. T.,
C. A. Smith,
N. J. McCarthy, and E. A. Grimes.
1992.
Apoptosis: final control point in cell biology.
Trends Cell Biol.
2:263-267.
[Medline] |
| 51.
|
Wyllie, A. H.
1987.
Apoptosis: cell death in tissue regulation.
J. Pathol.
153:313-316[Medline].
|
| 52.
|
Yao, R., and G. M. Cooper.
1995.
Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor.
Science
267:2003-2006[Abstract/Free Full Text].
|
| 53.
|
Yang, E.,
J. Zha,
J. Jockel,
L. H. Boise,
C. B. Thompson, and S. J. Korsmeyer.
1995.
Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces Bax and promotes cell death.
Cell
80:285-291[Medline].
|
| 54.
|
Yang, T.,
K. M. Kozopas, and R. W. Craig.
1995.
The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2.
J. Cell Biol.
128:1173-1184[Abstract/Free Full Text].
|
| 55.
|
Yen, J. J.-Y.,
Y. C. Hsieh,
C. L. Yen,
C. C. Chang,
S. Lin, and H. F. Yang-Yen.
1995.
Restoring the apoptosis suppression response to IL-5 confers on erythroleukemic cells a phenotype of IL-5-dependent growth.
J. Immunol.
154:2144-2152[Abstract].
|
| 56.
|
Yin, X.-M.,
Z. N. Oltvai, and S. J. Korsmeyer.
1994.
BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax.
Nature
369:321-323[Medline].
|
| 57.
|
Zha, J.,
H. Harada,
E. Yang,
J. Jockel, and S. J. Korsmeyer.
1996.
Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not Bcl-xL.
Cell
87:619-628[Medline].
|
| 58.
|
Zhou, P.,
L. Qian,
K. M. Kozopas, and R. W. Craig.
1997.
Mcl-1, a bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions.
Blood
89:630-643[Abstract/Free Full Text].
|
Mol Cell Biol, August 1998, p. 4883-4898, Vol. 18, No. 8
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Yang, C.-Y., Lin, N.-H., Lee, J.-M., Huang, C.-Y., Min, H.-J., Yen, J. J.-Y., Liao, N.-S., Yang-Yen, H.-F.
(2009). Promoter Knock-In Mutations Reveal a Role of Mcl-1 in Thymocyte-Positive Selection and Tissue or Cell Lineage-Specific Regulation of Mcl-1 Expression. J. Immunol.
182: 2959-2968
[Abstract]
[Full Text]
-
Son, K.-N., Becker, R. P., Kallio, P., Lipton, H. L.
(2008). Theiler's Virus-Induced Intrinsic Apoptosis in M1-D Macrophages Is Bax Mediated and Restricts Virus Infectivity: a Mechanism for Persistence of a Cytolytic Virus. J. Virol.
82: 4502-4510
[Abstract]
[Full Text]
-
Muto, A., Hori, M., Sasaki, Y., Saitoh, A., Yasuda, I., Maekawa, T., Uchida, T., Asakura, K., Nakazato, T., Kaneda, T., Kizaki, M., Ikeda, Y., Yoshida, T.
(2007). Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Molecular Cancer Therapeutics
6: 987-994
[Abstract]
[Full Text]
-
Dzhagalov, I., St. John, A., He, Y.-W.
(2007). The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages. Blood
109: 1620-1626
[Abstract]
[Full Text]
-
Chou, C.-H., Lee, R.-S., Yang-Yen, H.-F.
(2006). An Internal EELD Domain Facilitates Mitochondrial Targeting of Mcl-1 via a Tom70-dependent Pathway. Mol. Biol. Cell
17: 3952-3963
[Abstract]
[Full Text]
-
Liu, H., Eksarko, P., Temkin, V., Haines, G. K. III, Perlman, H., Koch, A. E., Thimmapaya, B., Pope, R. M.
(2005). Mcl-1 Is Essential for the Survival of Synovial Fibroblasts in Rheumatoid Arthritis. J. Immunol.
175: 8337-8345
[Abstract]
[Full Text]
-
Rahmani, M., Davis, E. M., Bauer, C., Dent, P., Grant, S.
(2005). Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation. J. Biol. Chem.
280: 35217-35227
[Abstract]
[Full Text]
-
Balakrishnan, K., Stellrecht, C. M., Genini, D., Ayres, M., Wierda, W. G., Keating, M. J., Leoni, L. M., Gandhi, V.
(2005). Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood
105: 4455-4462
[Abstract]
[Full Text]
-
Han, J., Goldstein, L. A., Gastman, B. R., Rabinovitz, A., Rabinowich, H.
(2005). Disruption of Mcl-1{middle dot}Bim Complex in Granzyme B-mediated Mitochondrial Apoptosis. J. Biol. Chem.
280: 16383-16392
[Abstract]
[Full Text]
-
Liu, H., Peng, H.-W., Cheng, Y.-S., Yuan, H. S., Yang-Yen, H.-F.
(2005). Stabilization and Enhancement of the Antiapoptotic Activity of Mcl-1 by TCTP. Mol. Cell. Biol.
25: 3117-3126
[Abstract]
[Full Text]
-
Aichberger, K. J., Mayerhofer, M., Krauth, M.-T., Skvara, H., Florian, S., Sonneck, K., Akgul, C., Derdak, S., Pickl, W. F., Wacheck, V., Selzer, E., Monia, B. P., Moriggl, R., Valent, P., Sillaber, C.
(2005). Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood
105: 3303-3311
[Abstract]
[Full Text]
-
Moshynska, O., Sankaran, K., Pahwa, P., Saxena, A.
(2004). Prognostic Significance of a Short Sequence Insertion in the MCL-1 Promoter in Chronic Lymphocytic Leukemia. JNCI J Natl Cancer Inst
96: 673-682
[Abstract]
[Full Text]
-
Crossley, L. J.
(2003). Neutrophil activation by fMLP regulates FOXO (forkhead) transcription factors by multiple pathways, one of which includes the binding of FOXO to the survival factor Mcl-1. J. Leukoc. Biol.
74: 583-592
[Abstract]
[Full Text]
-
Wang, J.-M., Lai, M.-Z., Yang-Yen, H.-F.
(2003). Interleukin-3 Stimulation of mcl-1 Gene Transcription Involves Activation of the PU.1 Transcription Factor through a p38 Mitogen-Activated Protein Kinase-Dependent Pathway. Mol. Cell. Biol.
23: 1896-1909
[Abstract]
[Full Text]
-
Woltman, A. M., van der Kooij, S. W., Coffer, P. J., Offringa, R., Daha, M. R., van Kooten, C.
(2003). Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood
101: 1439-1445
[Abstract]
[Full Text]
-
Channon, J. Y., Miselis, K. A., Minns, L. A., Dutta, C., Kasper, L. H.
(2002). Toxoplasma gondii Induces Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Secretion by Human Fibroblasts: Implications for Neutrophil Apoptosis. Infect. Immun.
70: 6048-6057
[Abstract]
[Full Text]
-
Gojo, I., Zhang, B., Fenton, R. G.
(2002). The Cyclin-dependent Kinase Inhibitor Flavopiridol Induces Apoptosis in Multiple Myeloma Cells through Transcriptional Repression and Down-Regulation of Mcl-1. Clin. Cancer Res.
8: 3527-3538
[Abstract]
[Full Text]
-
Zhang, D., Li, F., Weidner, D., Mnjoyan, Z. H., Fujise, K.
(2002). Physical and Functional Interaction between Myeloid Cell Leukemia 1 Protein (MCL1) and Fortilin. THE POTENTIAL ROLE OF MCL1 AS A FORTILIN CHAPERONE. J. Biol. Chem.
277: 37430-37438
[Abstract]
[Full Text]
-
Yu, Y.-L., Chiang, Y.-J., Yen, J. J. Y.
(2002). GATA Factors Are Essential for Transcription of the Survival Gene E4bp4 and the Viability Response of Interleukin-3 in Ba/F3 Hematopoietic Cells. J. Biol. Chem.
277: 27144-27153
[Abstract]
[Full Text]
-
Hartley, P. S., Bayne, R. A. L., Robinson, L. L. L., Fulton, N., Anderson, R. A.
(2002). Developmental Changes in Expression of Myeloid Cell Leukemia-1 in Human Germ Cells during Oogenesis and Early Folliculogenesis. J. Clin. Endocrinol. Metab.
87: 3417-3427
[Abstract]
[Full Text]
-
Zhang, B., Gojo, I., Fenton, R. G.
(2002). Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood
99: 1885-1893
[Abstract]
[Full Text]
-
Dijkers, P. F., Birkenkamp, K. U., Lam, E. W.-F., Thomas, N. S. B., Lammers, J.-W. J., Koenderman, L., Coffer, P. J.
(2002). FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. JCB
156: 531-542
[Abstract]
[Full Text]
-
Vrana, J. A., Bieszczad, C. K., Cleaveland, E. S., Ma, Y., Park, J. P., Mohandas, T. K., Craig, R. W.
(2002). An MCL1-overexpressing Burkitt Lymphoma Subline Exhibits Enhanced Survival on Exposure to Serum Deprivation, Topoisomerase Inhibitors, or Staurosporine but Remains Sensitive to 1-{beta}-D-Arabinofuranosylcytosine. Cancer Res.
62: 892-900
[Abstract]
[Full Text]
-
Kupfner, J. G., Arcaroli, J. J., Yum, H.-K., Nadler, S. G., Yang, K.-Y., Abraham, E.
(2001). Role of NF-{kappa}B in Endotoxemia-Induced Alterations of Lung Neutrophil Apoptosis. J. Immunol.
167: 7044-7051
[Abstract]
[Full Text]
-
Lin, M.-T., Juan, C.-Y., Chang, K.-J., Chen, W.-J., Kuo, M.-L.
(2001). IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1. Carcinogenesis
22: 1947-1953
[Abstract]
[Full Text]
-
Lin, Y.-H., Yang-Yen, H.-F.
(2001). The Osteopontin-CD44 Survival Signal Involves Activation of the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway. J. Biol. Chem.
276: 46024-46030
[Abstract]
[Full Text]
-
Moulding, D. A., Akgul, C., Derouet, M., White, M. R. H., Edwards, S. W.
(2001). BCL-2 family expression in human neutrophils during delayed and accelerated apoptosis. J. Leukoc. Biol.
70: 783-792
[Abstract]
[Full Text]
-
Chen, W., Yu, Y.-L., Lee, S.-F., Chiang, Y.-J., Chao, J.-R., Huang, J.-H., Chiong, J.-H., Huang, C.-J., Lai, M.-Z., Yang-Yen, H.-F., Yen, J. J.-Y.
(2001). CREB Is One Component of the Binding Complex of the Ces-2/E2A-HLF Binding Element and Is an Integral Part of the Interleukin-3 Survival Signal. Mol. Cell. Biol.
21: 4636-4646
[Abstract]
[Full Text]
-
Liu, H., Perlman, H., Pagliari, L. J., Pope, R. M.
(2001). Constitutively Activated Akt-1 Is Vital for the Survival of Human Monocyte-differentiated Macrophages: Role of Mcl-1, Independent of Nuclear Factor (NF)-{kappa}B, Bad, or Caspase Activation. JEM
194: 113-126
[Abstract]
[Full Text]
-
Epling-Burnette, P. K., Zhong, B., Bai, F., Jiang, K., Bailey, R. D., Garcia, R., Jove, R., Djeu, J. Y., Loughran, T. P. Jr., Wei, S.
(2001). Cooperative Regulation of Mcl-1 by Janus Kinase/STAT and Phosphatidylinositol 3-Kinase Contribute to Granulocyte-Macrophage Colony-Stimulating Factor-Delayed Apoptosis in Human Neutrophils. J. Immunol.
166: 7486-7495
[Abstract]
[Full Text]
-
Zhou, P., Levy, N. B., Xie, H., Qian, L., Lee, C.-Y. G., Gascoyne, R. D., Craig, R. W.
(2001). MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. Blood
97: 3902-3909
[Abstract]
[Full Text]
-
Moulding, D. A., Giles, R. V., Spiller, D. G., White, M. R. H., Tidd, D. M., Edwards, S. W.
(2000). Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 cells. Blood
96: 1756-1763
[Abstract]
[Full Text]
-
Huang, H.-M., Huang, C.-J., Yen, J. J.-Y.
(2000). Mcl-1 is a common target of stem cell factor and interleukin-5 for apoptosis prevention activity via MEK/MAPK and PI-3K/Akt pathways. Blood
96: 1764-1771
[Abstract]
[Full Text]
-
Leuenroth, S. J., Grutkoski, P. S., Ayala, A., Simms, H. H.
(2000). The loss of Mcl-1 expression in human polymorphonuclear leukocytes promotes apoptosis. J. Leukoc. Biol.
68: 158-166
[Abstract]
[Full Text]
-
Williams, D. P., Pirmohamed, M., Naisbitt, D. J., Uetrecht, J. P., Park, B. K.
(2000). Induction of Metabolism-Dependent and -Independent Neutrophil Apoptosis by Clozapine. Mol. Pharmacol.
58: 207-216
[Abstract]
[Full Text]
-
Lin, Y.-H., Huang, C.-J., Chao, J.-R., Chen, S.-T., Lee, S.-F., Yen, J. J.-Y., Yang-Yen, H.-F.
(2000). Coupling of Osteopontin and Its Cell Surface Receptor CD44 to the Cell Survival Response Elicited by Interleukin-3 or Granulocyte-Macrophage Colony-Stimulating Factor. Mol. Cell. Biol.
20: 2734-2742
[Abstract]
[Full Text]
-
Johnson, A. L.
(1999). Editorial: Mcl-1--Just Another Antiapoptotic Bcl-2 Homolog?. Endocrinology
140: 5465-5468
[Full Text]
-
Leo, C. P., Hsu, S. Y., Chun, S.-Y., Bae, H.-W., Hsueh, A. J. W.
(1999). Characterization of the Antiapoptotic Bcl-2 Family Member Myeloid Cell Leukemia-1 (Mcl-1) and the Stimulation of Its Message by Gonadotropins in the Rat Ovary. Endocrinology
140: 5469-5477
[Abstract]
[Full Text]
-
Lee, S.-F., Huang, H.-M., Chao, J.-R., Lin, S., Yang-Yen, H.-F., Yen, J. J.-Y.
(1999). Cytokine Receptor Common beta Chain as a Potential Activator of Cytokine Withdrawal-Induced Apoptosis. Mol. Cell. Biol.
19: 7399-7409
[Abstract]
[Full Text]
-
Wang, J.-M., Chao, J.-R., Chen, W., Kuo, M.-L., Yen, J. J.-Y., Yang-Yen, H.-F.
(1999). The Antiapoptotic Gene mcl-1 Is Up-Regulated by the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway through a Transcription Factor Complex Containing CREB. Mol. Cell. Biol.
19: 6195-6206
[Abstract]
[Full Text]
-
Huang, H.-M., Li, J.-C., Hsieh, Y.-C., Yang-Yen, H.-F., Yen, J. J.-Y.
(1999). Optimal Proliferation of a Hematopoietic Progenitor Cell Line Requires Either Costimulation With Stem Cell Factor or Increase of Receptor Expression That Can Be Replaced by Overexpression of Bcl-2. Blood
93: 2569-2577
[Abstract]
[Full Text]
-
Klampfer, L., Cammenga, J., Wisniewski, H.-G., Nimer, S. D.
(1999). Sodium Salicylate Activates Caspases and Induces Apoptosis of Myeloid Leukemia Cell Lines. Blood
93: 2386-2394
[Abstract]
[Full Text]
-
Townsend, K. J., Zhou, P., Qian, L., Bieszczad, C. K., Lowrey, C. H., Yen, A., Craig, R. W.
(1999). Regulation of MCL1 through a Serum Response Factor/Elk-1-mediated Mechanism Links Expression of a Viability-promoting Member of the BCL2 Family to the Induction of Hematopoietic Cell Differentiation. J. Biol. Chem.
274: 1801-1813
[Abstract]
[Full Text]
-
Lin, M.-T., Lee, R.-C., Yang, P.-C., Ho, F.-M., Kuo, M.-L.
(2001). Cyclooxygenase-2 Inducing Mcl-1-dependent Survival Mechanism in Human Lung Adenocarcinoma CL1.0 Cells. INVOLVEMENT OF PHOSPHATIDYLINOSITOL 3-KINASE/Akt PATHWAY. J. Biol. Chem.
276: 48997-49002
[Abstract]
[Full Text]
-
Bingle, C. D., Craig, R. W., Swales, B. M., Singleton, V., Zhou, P., Whyte, M. K. B.
(2000). Exon Skipping in Mcl-1 Results in a Bcl-2 Homology Domain 3 Only Gene Product That Promotes Cell Death. J. Biol. Chem.
275: 22136-22146
[Abstract]
[Full Text]
-
Bae, J., Leo, C. P., Hsu, S. Y., Hsueh, A. J. W.
(2000). MCL-1S, a Splicing Variant of the Antiapoptotic BCL-2 Family Member MCL-1, Encodes a Proapoptotic Protein Possessing Only the BH3 Domain. J. Biol. Chem.
275: 25255-25261
[Abstract]
[Full Text]
-
Dijkers, P. F., Birkenkamp, K. U., Lam, E. W.-F., Thomas, N. S. B., Lammers, J.-W. J., Koenderman, L., Coffer, P. J.
(2002). FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. JCB
156: 531-542
[Abstract]
[Full Text]